COMPELLING PRECLINICAL DATA FOR KAZIA’S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL
SYDNEY, Dec. 1, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of positive preclinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for…
Comments Off on COMPELLING PRECLINICAL DATA FOR KAZIA’S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL